---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-353278"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2026-08-17T12:30:07+00:00"
generated_at: "2026-08-17T12:35:58.858573+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Fulcrum to merge with Slate Medicines; Slate holders to own ~95% of combined company

## Summary
- Merger values Slate at $350M, Fulcrum at $31.3M; post-close ownership: Slate holders ~55.9%, investors ~39.1%, Fulcrum ~5.0%.
- $245M concurrent investment from existing Slate stockholders and new investors; combined cash runway into 2029.
- Fulcrum to pay $270M cash dividend to pre-merger Fulcrum stockholders; company renamed Slate Medicines, Inc.
- Fulcrum board set at 5 members, all designated by Slate; Fulcrum options with exercise price >$7.00 cancelled at close.
- Termination fees: Fulcrum pays $10M, Slate pays $15M; Slate stockholders holding 78.65% support deal.

## SEC filing metadata
- accession: 0001193125-26-353278
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2026-08-17T12:30:07+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312526353278/0001193125-26-353278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312526353278/d136791d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-353278
- JSON: https://secwatch.observer/filing/0001193125-26-353278.json
- Plain text: https://secwatch.observer/filing/0001193125-26-353278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.